Leerink Partnrs Analysts Raise Earnings Estimates for UTHR

United Therapeutics Co. (NASDAQ:UTHR) – Analysts at Leerink Partnrs raised their Q1 2025 EPS estimates for shares of United Therapeutics in a research report issued to clients and investors on Friday, April 25th. Leerink Partnrs analyst R. Ruiz now forecasts that the biotechnology company will post earnings of $6.48 per share for the quarter, up from their prior estimate of $6.32. The consensus estimate for United Therapeutics’ current full-year earnings is $24.48 per share. Leerink Partnrs also issued estimates for United Therapeutics’ Q2 2025 earnings at $7.20 EPS, Q3 2025 earnings at $8.08 EPS and Q4 2025 earnings at $7.82 EPS.

A number of other research analysts have also weighed in on UTHR. JPMorgan Chase & Co. reduced their price objective on shares of United Therapeutics from $357.00 to $355.00 and set an “overweight” rating for the company in a research note on Monday, April 21st. Bank of America upgraded United Therapeutics from an “underperform” rating to a “neutral” rating and set a $314.00 target price for the company in a research report on Monday, April 21st. StockNews.com raised United Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Thursday, April 17th. UBS Group raised their price target on United Therapeutics from $415.00 to $475.00 and gave the company a “buy” rating in a report on Wednesday, January 8th. Finally, Wells Fargo & Company reaffirmed an “equal weight” rating and issued a $314.00 price target (down previously from $395.00) on shares of United Therapeutics in a report on Friday, April 25th. Four analysts have rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, United Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $390.17.

United Therapeutics Trading Up 1.3 %

United Therapeutics stock opened at $300.76 on Monday. United Therapeutics has a 1-year low of $233.31 and a 1-year high of $417.82. The firm has a market capitalization of $13.51 billion, a price-to-earnings ratio of 13.21, a P/E/G ratio of 0.97 and a beta of 0.63. The firm has a 50 day simple moving average of $305.66 and a 200 day simple moving average of $345.68.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings data on Wednesday, February 26th. The biotechnology company reported $6.19 earnings per share for the quarter, beating analysts’ consensus estimates of $6.10 by $0.09. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The business had revenue of $735.90 million during the quarter, compared to analyst estimates of $734.74 million. During the same period in the previous year, the business earned $4.36 EPS.

Hedge Funds Weigh In On United Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the stock. TD Private Client Wealth LLC grew its position in United Therapeutics by 29.8% during the 1st quarter. TD Private Client Wealth LLC now owns 4,762 shares of the biotechnology company’s stock worth $1,468,000 after acquiring an additional 1,092 shares during the last quarter. Envestnet Asset Management Inc. increased its stake in shares of United Therapeutics by 18.1% during the first quarter. Envestnet Asset Management Inc. now owns 71,909 shares of the biotechnology company’s stock valued at $22,167,000 after buying an additional 11,029 shares during the period. Concurrent Investment Advisors LLC purchased a new position in shares of United Therapeutics during the first quarter valued at approximately $227,000. World Investment Advisors increased its stake in shares of United Therapeutics by 79.2% during the first quarter. World Investment Advisors now owns 2,328 shares of the biotechnology company’s stock valued at $718,000 after buying an additional 1,029 shares during the period. Finally, Brookstone Capital Management purchased a new position in shares of United Therapeutics during the first quarter valued at approximately $1,479,000. 94.08% of the stock is currently owned by institutional investors.

Insider Activity at United Therapeutics

In related news, EVP Paul A. Mahon sold 11,000 shares of the firm’s stock in a transaction that occurred on Thursday, April 3rd. The stock was sold at an average price of $306.18, for a total transaction of $3,367,980.00. Following the transaction, the executive vice president now directly owns 36,781 shares in the company, valued at $11,261,606.58. This trade represents a 23.02 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Michael Benkowitz sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $348.06, for a total value of $3,480,600.00. Following the transaction, the chief operating officer now owns 2,577 shares in the company, valued at approximately $896,950.62. The trade was a 79.51 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 74,500 shares of company stock valued at $24,472,050. Corporate insiders own 11.90% of the company’s stock.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.